News
The European Partnership for Personalised Medicine (EP PerMed) introduces two new opportunities for start-ups, researchers, and early-stage teams working on cutting-edge solutions in personalised medicine. These programmes aim to accelerate the development, validation, and market readiness of transformative innovations that enhance patient care:
Submission deadline is 13 March 2025
Find out more about both calls and how to apply on the EP PerMed website.
myOverview
Stay informed about Horizon Europe, Digital Europe & EDF, filtered on what matters to you.
Only for stakeholders located in Flanders
The European Partnership on One Health Antimicrobial Resistance (OH AMR) is about to launch the joint transnational call 2027 (JTC2027) “Understand, Model and Stop AMR Transmission”. The call opens on 18 November 2026. The call will follow a two-step evaluation process.Novel and improved measures are urgently required...
Read moreThe European Commission Directorate-General Research & Innovation has published ERA in Practice: A Guide for the R&I Community, developed with the support of INSPIRING ERA. The publication connects the four European Research Area policy priorities for joint action of the Pact for Research and Innovation (2021), with practical tools and...
Read moreNet4Society, the NCP network for Cluster 2, has published an updated edition of the document "Opportunities for Researchers from the Social Sciences and Humanities (SSH) in Horizon Europe". This document is designed to help potential applicants to find SSH-related call topics across the different parts of Horizon Europe in Work Programmes...
Read moreOn 5 November 2026, the European Commission published a correction for Horizon Europe topic HORIZON-CL6-2027-02-FARM2FORK-05. Under the section ‘Topic description - Scope’, the sentence on collaboration with projects funded under other topics in the work programme has been updated. The original text referred to...
Read moreTestimonial
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
